Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
Hemab Therapeutics (Nasdaq:COAG) reported Phase 2 long-term extension data for sutacimig in Glanzmann thrombasthenia and preclinical results in Factor VII deficiency at ISTH 2026. In 34 patients (median 6.9 months, up to 15.9), treated bleed rates fell, with no Grade 3+ related AEs. FDA endorsed a 0.2 mg/kg Q1 week Phase 3 plan in 2H 2026.
How this was made
The 30-second read
Why it matters
The article’s newest actionable elements are the Phase 2 LTE durability metrics, successful surgical hemostasis on study, and FDA endorsement of a specific Phase 3 dose/regimen (0.2 mg/kg Q1 week), which can shift expectations for trial readiness and near-term probability of success.
Market read
For COAG, the combination of durable LTE bleed reduction, manageable safety, and explicit Phase 3 dosing alignment is a meaningful de-risking catalyst ahead of Phase 3 initiation in 2H 2026.
What to watch
Thromboembolic events occurred in higher-exposure cohorts; traders may discount durability claims until the Phase 3 safety profile and TE mitigation strategy are validated.
Background
Hemab is a clinical-stage biotech developing sutacimig, a subcutaneous bispecific antibody aimed at prophylaxis for Glanzmann thrombasthenia (GT) and Factor VII deficiency (FVIID).
Ticker impact
Hemab reported sutacimig Phase 2 LTE results and FDA-endorsed Phase 3 dose/regimen (0.2 mg/kg Q1 week) for Glanzmann thrombasthenia and Factor VII deficiency.
Near-term upside bias versus peers on trial-readiness expectations; magnitude likely capped until Phase 3 endpoints and enrollment timelines are clearer.
The article discloses specific LTE outcomes (ATBR reductions, surgical hemostasis) and a specific FDA-endorsed Phase 3 dosing regimen, which can move sentiment and positioning, but it is still pre-Phase 3 efficacy confirmation.
Market effects
Supports the broader narrative that prophylactic, subcutaneous approaches may be feasible in rare bleeding disorders, potentially improving sentiment toward similar hemostasis platforms.
Limited direct regional read-through; primarily US-listed biotech sentiment with global conference visibility.
ISTH data can influence international trial design expectations and investor perception across Europe and North America for rare bleeding indications.
Counterpoint
LTE signals and FDA dose alignment do not guarantee Phase 3 efficacy; investors may fade the move if Phase 3 endpoints, comparator, or event rates prove less favorable.
Key entities
- companyHemab Therapeutics
Nasdaq-listed clinical-stage biotech presenting sutacimig clinical and preclinical data at ISTH 2026 and stating FDA alignment for Phase 3 dosing.
- product_candidateSutacimig
Subcutaneously administered bispecific antibody targeting endogenous Factor VIIa and TLT-1 to amplify thrombin generation for prophylaxis in GT and FVIID.
- regulatorFDA
Endorsed the clinical data package as sufficient to proceed to Phase 3 with a 0.2 mg/kg Q1 week regimen.
